AXIS MG Patient Registry

Summary

The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.

The main questions the registry aims to answer are:

* How do symptoms, daily functioning, and quality of life change over time?
* What treatments do participants use, and how are these treatments related to their symptoms and health?
* What challenges do participants experience with treatment, including side effects, treatment burden, missed doses, and access to care?

Participants will:

* Join the registry and complete an enrollment survey (online or through a mobile app)
* Complete a brief online survey about their MG approximately once a month
* Provide information that can help confirm their MG diagnosis
* Optionally, share their medical records with the research team

This is an observational study. The registry will not assign treatments or ask participants to change their medical care. Information collected through the registry may help researchers better understand MG and improve future research and care.

Conditions

• Myasthenia Gravis (MG)
• Myasthenia Gravis, Generalized
• Myasthenia Gravis, Ocular
• Myasthenia Gravis Crisis
• Myasthenia Gravis Associated With Thymoma
• Myasthenia Gravis Exacerbations
• Myasthenia Gravis Generalised
• Myasthenia Gravis Generalized
• Myasthenia Gravis, Thymectomy
• Myasthenia Gravis
• Myasthenia Gravis, MuSK
• AChR Myasthenia Gravis
• AChR-Ab Seropositive Generalized Myasthenia Gravis
• MG
• MG - Myasthenia Gravis

Sponsors & Collaborators

• Alira Health

  collaborator OTHER

• Autoimmune Neurology Alliance

  lead OTHER

Principal Investigators

• Richard J Nowak, MD, MS · Yale University

• Gary R Cutter, PhD · University of Alabama at Birmingham

• Neelam Goyal, MD · Stanford University

• Srikanth Muppidi, MD · Stanford University

• Jared R Adams, MD, PhD · Alira Health

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-03-19

Primary Completion

2036-03-31

Completion

2036-03-31

Countries

• United States

Study Locations